CUEDC2

CUEDC2 is a CUE-domain-containing adaptor protein that functions as a broad regulatory hub in inflammation, cell cycle control, and protein stability by scaffolding signaling complexes and directing ubiquitin-proteasome-mediated degradation of diverse substrates. In inflammatory signaling, CUEDC2 recruits PP1 phosphatase to IKKα/IKKβ to terminate NF-κB activation (PMID:18362886), stabilizes SOCS1 and SOCS3 through enhanced Elongin C/CUL2 association to suppress JAK1-STAT3 signaling (PMID:22084247, PMID:29991678), and directly binds NLRP3 to inhibit inflammasome-driven pyroptosis (PMID:41232582); Cuedc2-knockout mice accordingly exhibit excessive macrophage cytokine production and colitis susceptibility (PMID:24882011). In cell cycle regulation, Cdk1-dependent phosphorylation of CUEDC2 enables it to bind Cdc20 and release Mad2 from APC/C-Cdc20 to silence the spindle assembly checkpoint (PMID:21743465), while separately CUEDC2 inhibits APC/C-Cdh1 to stabilize Cyclin A and promote G1-S transition, a function terminated by ERK1/2-dependent phosphorylation and degradation of CUEDC2 upon UV damage (PMID:23776205). CUEDC2 also serves as a cofactor for TRIM-family E3 ligases, promoting TRIM33-mediated ubiquitination of GPX1 in cardiomyocytes (PMID:27286733) and TRIM21-mediated ubiquitination of CREB in glioma cells (PMID:33125618), and its CUE domain directly engages β-catenin to drive its nuclear translocation and Wnt target gene activation (PMID:36231027).

1. 2008 High

   Establishing CUEDC2 as a negative regulator of NF-κB signaling answered how IKK is dephosphorylated after inflammatory stimulation: CUEDC2 bridges IKK to the PP1 phosphatase complex via GADD34, and this complex disassembles upon TNF stimulation.

   Evidence Reciprocal co-immunoprecipitation, complex reconstitution, phosphorylation assays, and loss-of-function experiments in mammalian cells

   PMID:18362886

   Open questions at the time

   • Structural basis of the IKK-CUEDC2-PP1 ternary complex is unknown
   • Whether CUEDC2-PP1 acts on other kinases in the NF-κB pathway is untested
   • In vivo relevance in conditional knockout models was not shown
2. 2011 High

   Three simultaneous discoveries expanded CUEDC2 from an NF-κB regulator to a multi-pathway adaptor: it promotes ERα degradation via the ubiquitin-proteasome system, silences the spindle assembly checkpoint by releasing Mad2 from APC/C-Cdc20 after Cdk1 phosphorylation, and stabilizes SOCS3 to suppress JAK1-STAT3 signaling.

   Evidence Ubiquitin-proteasome assays for ERα degradation in breast cancer cells; RNAi, co-IP, live-cell imaging, and checkpoint assays for Cdc20-Mad2 regulation during mitosis; yeast two-hybrid, co-IP, and reporter assays for SOCS3-Elongin C stabilization

   PMID:21572428 PMID:21743465 PMID:22084247

   Open questions at the time

   • Whether CUE-domain ubiquitin binding is required for ERα degradation was not tested
   • Identity of the E3 ligase mediating CUEDC2-dependent ERα ubiquitination was unknown
   • How Cdk1-phosphorylated CUEDC2 specifically displaces Mad2 from the APC/C-Cdc20 complex structurally is unresolved
3. 2013 High

   Revealing that CUEDC2 also inhibits APC/C-Cdh1 to stabilize Cyclin A, and that UV-triggered ERK1/2 phosphorylation targets CUEDC2 for ubiquitin-dependent degradation, established CUEDC2 as a cell-cycle signal integrator whose own turnover controls the G1-S DNA damage checkpoint.

   Evidence Co-IP, ERK1/2 kinase assays, non-phosphorylatable mutant expression, cell cycle analysis after UV irradiation

   PMID:23776205

   Open questions at the time

   • The E3 ligase responsible for CUEDC2 degradation after ERK-dependent phosphorylation is not identified
   • Whether this mechanism operates in non-transformed cells in vivo is untested
4. 2014 High

   In vivo loss-of-function in Cuedc2 knockout mice demonstrated that CUEDC2 is essential for macrophage inflammatory homeostasis and that its absence leads to excessive cytokine production, colitis, and colitis-associated cancer, confirming a non-redundant physiological role.

   Evidence Cuedc2 KO mice, DSS colitis and colitis-associated cancer models, macrophage transplantation rescue, miR-324-5p target validation

   PMID:24882011

   Open questions at the time

   • Which downstream pathway (NF-κB, JAK-STAT, or both) drives the colitis phenotype was not dissected
   • Tissue-specific conditional knockouts were not reported
5. 2014 Medium

   Identification of HSP70 as a CUE-domain-dependent binding partner revealed that CUEDC2 can negatively regulate protein chaperone activity, extending its functional repertoire beyond signaling and cell cycle.

   Evidence Affinity purification–mass spectrometry, co-IP with domain mapping, intracellular luciferase refolding assay

   PMID:24685480

   Open questions at the time

   • Only a single chaperone substrate (luciferase) was tested
   • Physiological consequence of HSP70 inhibition by CUEDC2 is not established in vivo
   • No independent replication
6. 2016 High

   Demonstrating that CUEDC2 facilitates TRIM33-mediated ubiquitination and degradation of GPX1 in cardiomyocytes established CUEDC2 as a cofactor for TRIM-family E3 ligases and linked it to oxidative stress defense in the heart.

   Evidence Cuedc2 KO mice, ubiquitination reconstitution, ischemia/reperfusion injury model, GPX1 stability assays

   PMID:27286733

   Open questions at the time

   • Whether CUEDC2 is a general TRIM33 cofactor or specific to GPX1 is unclear
   • Structural basis for CUEDC2-TRIM33 cooperation is unknown
7. 2018 Medium

   Extending the SOCS-stabilization mechanism to SOCS1 via Elongin C/CUL2 in AML cells generalized the principle that CUEDC2 enhances SOCS-box E3 ligase complex assembly to suppress JAK-STAT signaling across cell types.

   Evidence Co-IP, ubiquitination and stability assays, CUEDC2 overexpression/knockdown in AML cell lines

   PMID:29991678

   Open questions at the time

   • Whether CUEDC2 engages SOCS proteins directly or via Elongin C is not resolved structurally
   • Independent replication in primary AML samples is lacking
8. 2020 Medium

   Showing that CUEDC2 promotes TRIM21-mediated ubiquitination of CREB and that this axis controls GDNF transcription in glioma revealed a second TRIM-family partnership and a transcription-factor-degradation role for CUEDC2.

   Evidence Co-IP, ubiquitination assays, ChIP for GDNF promoter CREB occupancy in glioma cells

   PMID:33125618

   Open questions at the time

   • Whether CUEDC2-TRIM21 cooperates on substrates beyond CREB is unknown
   • Single lab, no in vivo validation
9. 2022 High

   Mapping the CUE domain interaction with β-catenin ARM repeats 7–9 and blocking it with a competitive peptide demonstrated that CUEDC2 directly promotes β-catenin nuclear translocation and Wnt target gene activation, revealing a new signaling axis targetable therapeutically.

   Evidence Pull-down, SPR binding, LC-MS/MS, nuclear translocation assays, competitive 11-mer peptide inhibition in vitro and in vivo xenografts

   PMID:36231027

   Open questions at the time

   • Whether CUEDC2 competes with APC/Axin destruction complex components for β-catenin binding is untested
   • Selectivity and pharmacokinetics of the competitive peptide in vivo are preliminary
10. 2022 Medium

    Linking CUEDC2-dependent ERα degradation specifically to mitosis-specific phosphorylation of CUEDC2 unified the earlier ERα and mitotic-checkpoint findings, showing that the same phospho-regulated switch governs both checkpoint silencing and ERα turnover.

    Evidence Cell cycle synchronization, phosphorylation site analysis, co-IP, ubiquitination assays, aneuploidy quantification

    PMID:35732909

    Open questions at the time

    • The E3 ligase mediating mitotic ERα ubiquitination downstream of CUEDC2 remains unidentified
    • Whether mitotic ERα degradation is relevant in normal mammary tissue is unknown
11. 2025 Medium

    Discovery that CUEDC2 directly binds NLRP3 and inhibits inflammasome activation extended its anti-inflammatory repertoire beyond NF-κB and JAK-STAT to the innate immune inflammasome pathway.

    Evidence Co-IP, CUEDC2 overexpression/knockdown, caspase-1 and IL-1β maturation assays in glomerular endothelial cells

    PMID:41232582

    Open questions at the time

    • Mechanism of NLRP3 inhibition (oligomerization block vs. ASC recruitment block) is not defined
    • In vivo relevance in inflammasome-driven disease models is not shown
    • No independent replication

• A unified structural model explaining how the CUE domain selectively engages its many partners (IKK, Cdc20, SOCS proteins, TRIMs, β-catenin, NLRP3, HSP70, ubiquitin), and how phosphorylation switches redirect CUEDC2 among these interactions, remains unresolved.
• No high-resolution structure of CUEDC2 or its complexes exists
• Quantitative binding affinities for most partners have not been measured
• How the cell prioritizes CUEDC2 allocation among competing interactions is unknown